Medicare Part D coverage · roflumilast · RxCUI 1091843

roflumilast 0.5 MG Oral Tablet [Daliresp]

Per the CMS 2026 Part D formulary file, roflumilast 0.5 MG Oral Tablet [Daliresp] is covered by 6 Medicare Part D plans (0.1% of enrollable products), averaging Tier 2.5, with prior authorization required on 100% of covering formularies.

0.1%
Plan coverage
6
Plans covering
T2.5
Avg tier
100%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for roflumilast 0.5 MG Oral Tablet [Daliresp]

Per the CMS 2026 Part D formulary file, roflumilast 0.5 MG Oral Tablet [Daliresp] (RxNorm concept RXCUI 1091843, generic name roflumilast) appears on 2 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.

Real-world access to roflumilast 0.5 MG Oral Tablet [Daliresp] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 59,491 Part D beneficiaries filled roflumilast 0.5 MG Oral Tablet [Daliresp] in 2023, with total plan-and-beneficiary spending of $60,127,502 and an average per-beneficiary annual cost of $1,010.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry roflumilast 0.5 MG Oral Tablet [Daliresp] today.

Coverage Details

Formularies covering
2
Plans covering
6
Coverage rate
0.1%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
100% of formularies
Step therapy required
0% of formularies
Quantity limits
100% of formularies

2023 Medicare Spending

Beneficiaries
59,491
Total spending
$60,127,502
Avg per beneficiary
$1,010.70

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic
4 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering roflumilast 0.5 MG Oral Tablet [Daliresp]

6 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) Hamaspik, Inc. T1 Yes $0 NY
Hamaspik Medicare Select (HMO D-SNP) Hamaspik, Inc. T1 Yes $34.50 NY
Health New England Medicare Compass (PPO) Health NEW England, Inc. T4 Yes $0 MA
Health New England Medicare Value (HMO) Health NEW England, Inc. T4 Yes $0 MA
Health New England Medicare Premium (HMO) Health NEW England, Inc. T4 Yes $15.80 MA
Health New England Medicare Plus (HMO) Health NEW England, Inc. T4 Yes $58.40 MA

Frequently Asked Questions

Is roflumilast 0.5 MG Oral Tablet [Daliresp] covered by Medicare Part D?

Yes, roflumilast 0.5 MG Oral Tablet [Daliresp] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).

What tier is roflumilast 0.5 MG Oral Tablet [Daliresp] on Medicare Part D plans?

roflumilast 0.5 MG Oral Tablet [Daliresp] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.

Does roflumilast 0.5 MG Oral Tablet [Daliresp] require prior authorization?

100% of Part D formularies require prior authorization for roflumilast 0.5 MG Oral Tablet [Daliresp]. Step therapy: 0%. Quantity limits: 100%.

How much does Medicare spend on roflumilast 0.5 MG Oral Tablet [Daliresp]?

In 2023, total Medicare Part D spending on roflumilast 0.5 MG Oral Tablet [Daliresp] was $60,127,502, covering 59,491 beneficiaries. The average spend per beneficiary was $1,010.70.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare